NAD+ Therapy: How Cellular Energy Restoration Actually Works

The conversation around NAD+ therapy has become noisy. Influencers describe it as an anti-aging miracle. Skeptics dismiss it as an expensive vitamin. Both miss what the molecule actually is and what restoring it actually does. NAD+ is not a hormone, a peptide, or a stimulant. It is a coenzyme that every cell in the body needs in stoichiometric quantities to convert food into usable energy and to repair its own DNA. When tissue concentrations fall — and they do fall, measurably, with age — the downstream chemistry slows. Prescribed NAD+ therapy is the clinical attempt to reverse that decline at the level of the molecule itself.

This article walks through what NAD+ does inside the cell, why levels drop, how a licensed NAD+ injection differs from oral supplementation, and what the human evidence supports. The goal is not to sell the molecule. It is to describe it accurately so a patient considering the protocol can evaluate whether it fits their clinical picture.

What NAD+ does inside the cell

NAD+ is a redox coenzyme. In its oxidized form (NAD+) it accepts electrons; in its reduced form (NADH) it carries them. This electron-shuttling is the chemistry behind cellular respiration. Glycolysis, the citric acid cycle, and the electron transport chain all depend on the NAD+/NADH couple to extract energy from glucose, fatty acids, and amino acids. Without enough NAD+ in circulation, the upstream reactions stall and the mitochondrial energy output of the cell drops.

The coenzyme has a second job that is less commonly discussed but mechanistically just as important. Sirtuins — the SIRT1 through SIRT7 family of enzymes — consume NAD+ as a substrate when they deacetylate proteins involved in stress response, DNA repair, and metabolic regulation. Sirtuin activation is therefore NAD+-dependent: when intracellular NAD+ is high, sirtuins run; when it is low, they slow down. PARP enzymes that repair DNA strand breaks have the same dependency, consuming NAD+ each time they detect and patch damage.

The cell, in other words, uses NAD+ for two things simultaneously: producing energy and maintaining its own genome. Both functions degrade in parallel when the NAD+ pool falls.

Why NAD+ levels decline

Aging humans show a roughly 50% reduction in tissue NAD+ between young adulthood and middle age across most peer-reviewed assays. The decline is driven by two separate mechanisms operating at once.

The first is increased consumption. CD38, an ectoenzyme that hydrolyzes NAD+, rises substantially with age in immune and metabolic tissues; it is now considered one of the dominant consumers of cellular NAD+ in older adults. PARP enzymes also consume more NAD+ as they respond to the accumulated DNA damage that is itself a feature of aging. Chronic inflammation drives both.

The second mechanism is reduced production. NAD+ is synthesized through the salvage pathway, which recycles nicotinamide back to NAD+ via NAMPT, a rate-limiting enzyme. NAMPT activity declines with age. Dietary precursor intake — niacin, nicotinamide, and the smaller contributions from tryptophan — is rarely sufficient to fully replace what aging tissues are losing.

The result is a slow drift downward. By the fifth and sixth decade of life, the NAD+ available for mitochondrial chemistry and sirtuin signaling is meaningfully reduced compared with what the same tissue carried at age 25.

Why oral supplements underperform

Oral NAD+ products fall into two categories. Direct NAD+ capsules are largely hydrolyzed in the digestive tract before the molecule can cross the intestinal wall intact. The bioavailable fraction is small. NAD+ precursors — nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) — are more stable, but they still face first-pass liver metabolism, and the conversion to NAD+ in peripheral tissues depends on transport and enzymatic capacity that varies by tissue.

The practical consequence is that oral supplementation does raise circulating markers, but the magnitude of the rise — and the tissue distribution of that rise — is modest compared to what the same patient would achieve through a parenteral route. A 600 mg oral NR dose can produce a measurable but limited increase in whole-blood NAD+. A clinician-prescribed subcutaneous NAD+ injection delivers the molecule to circulation directly and produces a different concentration profile.

This is not a marketing distinction. It is a pharmacokinetic one. The same molecule, delivered through different routes, reaches different concentrations in different tissues at different rates. Prescribed NAD+ is dosed and monitored against this reality.

What the human evidence actually supports

The clinical literature splits into two streams. The precursor-trial stream — NR and NMN given orally in randomized controlled designs — is the larger and more rigorous body of work. These trials have repeatedly shown that oral precursors raise tissue NAD+ measurably, that the increase is sustained over weeks of dosing, and that subjective energy and certain inflammatory markers move in directions consistent with the mechanism. Effects on mitochondrial function as measured by 31P-MRS phosphocreatine recovery have been reproduced in older adults.

The direct NAD+ stream — IV and subcutaneous protocols — has a smaller evidence base, mostly from clinical observation series, open-label studies, and a handful of controlled designs. The patterns are consistent across these reports: improvements in subjective energy, reduced perception of fatigue, and quality-of-life signals. The longevity and lifespan claims that circulate in popular media outrun the data; the energy, recovery, and metabolic claims do not.

A clinician interpreting this literature reasonably concludes that NAD+ therapy is a defensible intervention for a defined clinical picture — patients with documented fatigue, recovery deficits, or mitochondrial-function complaints — while remaining honest that it is not a proven anti-aging therapy in the way that some marketing implies.

How a clinician sets dose and cadence

Prescribed protocols are individualized. Common starting ranges for subcutaneous NAD+ are in the 50 to 100 mg per dose band, administered two to five times per week depending on patient response. Dose is escalated cautiously based on tolerability — flushing and warmth at the injection site are common at higher concentrations — and adjusted against patient-reported energy and recovery signals. Some patients hold a low dose indefinitely; others tolerate and benefit from higher concentrations.

The clinician monitors for the effects that should appear if the protocol is working: better recovery between training sessions, more stable afternoon energy, improved sleep quality, and in some cases improvements in cognitive endpoints that the patient tracks subjectively. The clinician also monitors for the things that should not happen: persistent headache, GI symptoms, or significant changes in cardiovascular endpoints. If the protocol is not producing the expected response after a defined trial period, it is discontinued, not escalated indefinitely.

How TelePeptide handles NAD+

NAD+ therapy sits inside the Recovery & Performance track. Eligibility is reviewed individually by a licensed clinician based on history, goals, and labs. Dose, cadence, and protocol length are physician-determined, not patient-selected. Compounded preparations are sourced from licensed 503A pharmacies. Compounded medications are not FDA-approved. These statements have not been evaluated by the FDA. The program is designed for patients who want a measurable mitochondrial input under clinical supervision, not a self-directed supplement experiment.